TNI BioTech to Present at 6th Annual OneMedForum San Francisco 2013
NEW YORK and POTOMAC, Md., Jan. 3, 2013 /PRNewswire/ -- TNI BioTech, Inc. (PINKSHEETS: TNIB), a public company operating in the biotech sector, today announced that Noreen McGurrin Griffin, Chief Executive Officer, and Dr. Ronald Herberman, Chief Medical Officer, are scheduled to speak at the 6th Annual OneMedForum at the Sir Frances Drake Hotel, San Francisco, CA on January 7-9, 2013.
Ms. Griffin and Dr. Herberman intend to provide an update on the company's business activities for 2012 and plans for 2013. TNI BioTech's presentation is scheduled for Wednesday, January 9, 2013 at 11:20 am PST (2:20 pm Eastern Standard Time).
About TNI BioTech, Inc.
TNI BioTech, Inc., is a biotech company working to combat fatal diseases through the activation and mobilization of the body's immune system using our patented immunotherapy. Our products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.
Our proprietary technology, therapies and patents, will be used to treat a wide range of cancers. Our most advanced clinical programs involve immunotherapy that works by isolating a patient's lymphocytes and then incubating them together with Methionine Enkephalin (MENK) in an enriching external incubation system. After incubation the patient's lymphocytes are re-infused back into the patient where they combat and destroy tumor cells.
However, even though Management considers any condition that results in altered-immune response a target for investigation, the Company will most likely pursue additional investigations for MENK as a valuable candidate in the treatment of the following:
- Autoimmune states such as rheumatoid arthritis and multiple sclerosis;
- As an adjunct to antibiotics in the treatment of infectious diseases;
- In cancer patients undergoing chemotherapy, radiation treatments or surgery;
- Patients with AIDS, in combination with retroviral drug therapy; and
- In wound healing or herpes viral infections.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release includes various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which represent the Company's expectations or beliefs concerning future events. Statements containing expressions such as "believes," "anticipates," "intends," or "expects," used in the Company's press releases and in Disclosure Statements and Reports filed with the Over The Counter Markets through the OTC Disclosure and News Service are intended to identify forward-looking statements. All forward-looking statements involve risks and uncertainties. Although the Company believes its expectations are based upon reasonable assumptions within the bounds of its knowledge of its business and operations, there can be no assurances that actual results will not differ materially from expected results. The Company cautions that these and similar statements included in this report are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date thereof. The Company undertakes no obligation to publicly release any revisions to such forward-looking statements to reflect events or circumstances after the date hereof.
See http://www.tnibiotech.com for more information.
Contact: Global Investment Media
SOURCE TNI BioTech, Inc.